Presence of SARS-CoV-2 in middle ear fluid and characterization of otitis media with effusion in COVID-19 patients
Highlights
Objective
This study sought to determine whether SARS-CoV-2 is present in the middle ear fluid (MEF) of COVID-19 patients who have otitis media with effusion (OME).
Methods
A case-control study was designed to detect SARS-CoV-2 and six other common respiratory viruses (influenza A virus, influenza B virus, respiratory syncytial virus, adenovirus, human rhinovirus (HRV), and mycoplasma pneumonia) by PCR in the MEF of patients with OME. Follow-up tests, including pure-tone audiometry and tympanometry, were conducted.
Results
In the COVID-19 group, 18 of 27 MEF specimens were PCR-positive for SARS-CoV-2, with cycle thresholds ranging from 24.9 to 42.2. And one patient tested positive for the HRV. In the control group, all 15 MEF specimens were PCR-negative for SARS-CoV-2, but 2 patients tested positive for the HRV. After treatment for OME, 11 patients (40.7%) reported complete resolution, 14 (51.9%) reported improvement, and 2 (7.4%) reported no change. The average improvement in hearing was 14.5 ± 8.1 dB, and the average air-bone gap decrease was 13.5 ± 9.0 dB.
Conclusions
This study confirmed the presence of SARS-CoV-2 in the MEF of patients who were previously COVID-19-positive suggesting a possible association between COVID-19 and OME. OME should be considered a possible symptom of COVID-19.
Highlights
- The role of SARS-CoV-2 in OME is currently unknown.
- Eighteen out of 27 MEF specimens of COVID-19 group tested positive for SARS-CoV-2.
- The presence of SARS-CoV-2 in MEF suggests that OME may be a symptom of COVID-19.
Objective
This study sought to determine whether SARS-CoV-2 is present in the middle ear fluid (MEF) of COVID-19 patients who have otitis media with effusion (OME).
Methods
A case-control study was designed to detect SARS-CoV-2 and six other common respiratory viruses (influenza A virus, influenza B virus, respiratory syncytial virus, adenovirus, human rhinovirus (HRV), and mycoplasma pneumonia) by PCR in the MEF of patients with OME. Follow-up tests, including pure-tone audiometry and tympanometry, were conducted.
Results
In the COVID-19 group, 18 of 27 MEF specimens were PCR-positive for SARS-CoV-2, with cycle thresholds ranging from 24.9 to 42.2. And one patient tested positive for the HRV. In the control group, all 15 MEF specimens were PCR-negative for SARS-CoV-2, but 2 patients tested positive for the HRV. After treatment for OME, 11 patients (40.7%) reported complete resolution, 14 (51.9%) reported improvement, and 2 (7.4%) reported no change. The average improvement in hearing was 14.5 ± 8.1 dB, and the average air-bone gap decrease was 13.5 ± 9.0 dB.
Conclusions
This study confirmed the presence of SARS-CoV-2 in the MEF of patients who were previously COVID-19-positive suggesting a possible association between COVID-19 and OME. OME should be considered a possible symptom of COVID-19.
